Sun Pharma’s specialty portfolio, Organon deal to drive growth
Economic Times
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although…
Summary from Economic Times
Read the full story on Economic TimesFollow






